Kintor Pharmaceutical Limited (HKG:9939)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.910
+0.030 (1.04%)
At close: Mar 6, 2026
Market Cap1.44B +252.9%
Revenue (ttm)12.04M
Net Income-183.07M
EPS-0.42
Shares Out493.52M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,694,500
Average Volume2,070,625
Open2.880
Previous Close2.880
Day's Range2.830 - 2.980
52-Week Range1.050 - 3.150
Beta-0.58
RSI62.70
Earnings DateMar 26, 2026

About Kintor Pharmaceutical

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 136
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9939
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements